December 18, 2024

Does Anger at Health Care Drive Change?

In-depth exploration of public anger towards the American health care system throughout history, potential for change, and Hollywood's portrayal of health insurance-related events.

KFF Health News

December 17, 2024

Trump's Health Picks Clash on Vaccines, Policy

The selection of individuals for federal health agencies under President-elect Donald Trump presents conflicting views on matters such as abortion limits, vaccine safety, covid-19 responses, and the use of weight-loss medications.

KFF Health News

December 17, 2024

FDA Rejects J&J’s Injectable Lung Cancer Drug

FDA declines to approve Johnson & Johnson's Rybrevant injectable for non-small cell lung cancer due to observations during pre-approval inspection unrelated to drug formulation, efficacy, or safety. J&J is working to resolve the issues.

Reuters

December 17, 2024

Pfizer: No Major Vaccine Shifts in 2025

Pfizer's CEO addressed the impact of potential vaccine policy changes and the nomination of a vaccine skeptic to run the Department of Health and Human Services, highlighting the company's commitment to advancing the right policies and overcoming challenges in the pharmaceutical market.

Reuters

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 12, 2024

Trump, RFK Jr. Eye Vaccine Policies

Trump plans to discuss vaccine programs with RFK Jr., citing potential risks and the autism rate as key concerns.

Reuters

December 05, 2024

FDA Approves Imfinzi for Limited Stage SCLC

In a late-stage trial, the drug showed statistically significant improvement in overall survival compared to a placebo.

Reuters

December 05, 2024

FDA Grants Approval to New Bispecific Antibody for NSCLC and Pancreatic Adenocarcinoma

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to the HER2 × HER3 bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with advanced or metastatic NRG1...

The ASCO Post

December 05, 2024

Bizengri Gets FDA Nod for Cancer

The recommended dose of the therapy is 750 milligrams as an intravenous infusion every 2 weeks.

Reuters